Fig. 1: Survival of patients with EGFR amplification in breast cancer. | Oncogene

Fig. 1: Survival of patients with EGFR amplification in breast cancer.

From: EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition

Fig. 1

A Combination of TCGA, METABRIC, MSKCC datasets to analyze overall survival (OS) of patients comparing EGFR amplification (red line) to patients without EGFR amplification (blue line). B OS of patients from Caris dataset with EGFR amplification (red line) compared to patients without EGFR amplification (blue line).

Back to article page